{"id":"citalopram-hcl","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"8-12","effect":"Dry mouth"},{"rate":"8-12","effect":"Diarrhea"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Citalopram is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the extracellular space, enhancing serotonergic neurotransmission. The enhanced serotonin signaling is thought to improve mood and alleviate symptoms of depression and anxiety disorders.","oneSentence":"Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:36.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT04846829","phase":"EARLY_PHASE1","title":"Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-04-24","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT07113145","phase":"PHASE4","title":"Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-01","conditions":"Premature (Early) Ejaculation","enrollment":450},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT00667121","phase":"","title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-03-16","conditions":"Breast Cancer, Depression, Hot Flashes","enrollment":88},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT04245436","phase":"PHASE4","title":"Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-01-01","conditions":"Anxiety, Depressive Symptoms","enrollment":60},{"nctId":"NCT04245748","phase":"PHASE4","title":"Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-03-01","conditions":"Anxious Depression, Depression","enrollment":84},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT04476030","phase":"PHASE3","title":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-11-09","conditions":"Depressive Disorder, Major","enrollment":440},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT01742832","phase":"PHASE2","title":"Double-Blind Treatment of Major Depressive Disorder With Vilazodone","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-05","conditions":"Major Depressive Disorder","enrollment":79},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05730062","phase":"PHASE1","title":"Influence of Oxycodone on Individuals Taking an SSRI","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-03-15","conditions":"Opioid Induced Respiratory Depression, Depressive Disorder, Anxiety Disorders","enrollment":55},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT04697693","phase":"PHASE4","title":"Antidepressant Response in Older Adults With Comorbid PTSD and MDD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-03","conditions":"Post Traumatic Stress Disorder, Major Depressive Disorder","enrollment":1},{"nctId":"NCT04923321","phase":"","title":"Taste Supra-thresholds Among a Sample of Depressed Egyptian Adult Under Anti-depressants Therapy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-02-22","conditions":"Taste Disorders","enrollment":30},{"nctId":"NCT03321006","phase":"PHASE4","title":"Treating Hearing Loss to Improve Mood and Cognition in Older Adults","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2018-05-30","conditions":"Hearing Loss, Depression","enrollment":25},{"nctId":"NCT03294525","phase":"","title":"Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-01","conditions":"Affective Disorder","enrollment":400},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT04923425","phase":"","title":"Gustatory Modulators Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-02-22","conditions":"Taste Disorders","enrollment":30},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT03068429","phase":"PHASE4","title":"Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-12-01","conditions":"Obsessive-Compulsive Disorder","enrollment":69},{"nctId":"NCT04806230","phase":"","title":"Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study","status":"COMPLETED","sponsor":"Linkoeping University","startDate":"2011-04-01","conditions":"Pharmacokinetics, Antidepressive Agents, Pregnancy","enrollment":81},{"nctId":"NCT03599011","phase":"","title":"Gustatory Dysfunction Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-02-22","conditions":"Taste Disorders","enrollment":30},{"nctId":"NCT01973283","phase":"PHASE4","title":"Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02-19","conditions":"Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS","enrollment":100},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT03487211","phase":"PHASE2, PHASE3","title":"Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2018-04-09","conditions":"Fibromyalgia","enrollment":200},{"nctId":"NCT02191397","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-10","conditions":"Depressive Disorder, Major","enrollment":534},{"nctId":"NCT03148522","phase":"NA","title":"A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System","status":"UNKNOWN","sponsor":"Peking University","startDate":"2017-06-01","conditions":"Diagnosis and Treatment of Depression","enrollment":120},{"nctId":"NCT02869035","phase":"PHASE1","title":"Treatment Outcome in Major Depressive Disorder","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-08","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT03623711","phase":"EARLY_PHASE1","title":"A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression","status":"UNKNOWN","sponsor":"Yuqi Cheng","startDate":"2018-08-01","conditions":"Major Depressive Disorder, Depression, Unipolar","enrollment":200},{"nctId":"NCT03746691","phase":"PHASE4","title":"Effect of Citalopram on Reflux Episodes in Healthy Volunteers","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-02-01","conditions":"Gastro Esophageal Reflux","enrollment":19},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT00693849","phase":"PHASE4","title":"International Study to Predict Optimised Treatment - in Depression","status":"UNKNOWN","sponsor":"BRC Operations Pty. Ltd.","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":2688},{"nctId":"NCT02441387","phase":"","title":"Predictors of the Outcome of Late Life Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT01658228","phase":"PHASE4","title":"Combination Treatment Study for Memory Impairment and Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-09","conditions":"Depression, Mild Cognitive Impairment","enrollment":86},{"nctId":"NCT01148472","phase":"PHASE4","title":"Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2005-09","conditions":"Major Depressive Disorder","enrollment":294},{"nctId":"NCT02028026","phase":"PHASE4","title":"The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2013-04","conditions":"Major Depressive Disorder, Anxiety, Comorbidity","enrollment":""},{"nctId":"NCT02934035","phase":"","title":"Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":10000},{"nctId":"NCT00360399","phase":"NA","title":"Identifying Factors That Predict Antidepressant Treatment Response","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-08","conditions":"Depression","enrollment":344},{"nctId":"NCT02023567","phase":"NA","title":"Objective Diagnostic Markers and Personalized Intervention in MDD Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2013-11","conditions":"Depressive Disorder, Major","enrollment":2400},{"nctId":"NCT02320240","phase":"","title":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-06","conditions":"Depression, Acute Kidney Injury","enrollment":3255526},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT00817011","phase":"NA","title":"Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2006-04","conditions":"Depression, Antidepressant Drug Adverse Reaction","enrollment":1000},{"nctId":"NCT01369095","phase":"PHASE2","title":"Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-07","conditions":"Depression","enrollment":976},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01796132","phase":"PHASE4","title":"Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-08","conditions":"Depressive Disorder, Lactation","enrollment":500},{"nctId":"NCT00974155","phase":"PHASE4","title":"The Early Medication Change (EMC) Trial","status":"COMPLETED","sponsor":"K. Lieb","startDate":"2009-09","conditions":"Depression","enrollment":889},{"nctId":"NCT01436643","phase":"PHASE4","title":"Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Depression, Relapsing-remitting Multiple Sclerosis","enrollment":54},{"nctId":"NCT02237937","phase":"PHASE4","title":"Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene","status":"UNKNOWN","sponsor":"HolsboerMaschmeyer NeuroChemie GmbH","startDate":"2011-09","conditions":"Major Depression","enrollment":80},{"nctId":"NCT01473381","phase":"PHASE4","title":"Safety and Efficacy of Vilazodone in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Major Depressive Disorder","enrollment":1162},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT02179268","phase":"PHASE3","title":"Antidepressants and Bone Mineral Density","status":"COMPLETED","sponsor":"Guiyang Medical University","startDate":"2012-03","conditions":"Bone Mineral Density Quantitative Trait Locus 7","enrollment":203},{"nctId":"NCT00018902","phase":"PHASE2, PHASE3","title":"Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-01","conditions":"Depression","enrollment":334},{"nctId":"NCT01601912","phase":"","title":"Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2013-02","conditions":"Whiplash Injuries","enrollment":59},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00177671","phase":"PHASE4","title":"Antidepressant Medication Plus Donepezil for Treating Late-life Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-12","conditions":"Depression, Dementia","enrollment":220},{"nctId":"NCT01404871","phase":"NA","title":"Predicting Medication Response in Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2009-04","conditions":"Obsessive Compulsive Disorder","enrollment":26},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080},{"nctId":"NCT00944996","phase":"NA","title":"Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression","status":"COMPLETED","sponsor":"Tirat Carmel Mental Health Center","startDate":"2009-06","conditions":"Major Depression","enrollment":100},{"nctId":"NCT00985504","phase":"PHASE4","title":"A Study of Patients With Major Depressive Disorder and Residual Apathy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Major Depressive Disorder","enrollment":483},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT01369290","phase":"","title":"Electroencephalography (EEG) Signal Processing","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2009-10","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT00810069","phase":"PHASE4","title":"Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-11","conditions":"Major Depressive Disorder","enrollment":840},{"nctId":"NCT00051272","phase":"PHASE3","title":"Effects Of Antidepressants On Sexual Functioning In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":425},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00051259","phase":"PHASE3","title":"Effects of Antidepressants on Sexual Functioning","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Major Depressive Disorder (MDD)","enrollment":420},{"nctId":"NCT00666757","phase":"PHASE4","title":"A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-05","conditions":"Depression","enrollment":750},{"nctId":"NCT01078870","phase":"PHASE4","title":"Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-02","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00432614","phase":"PHASE3","title":"Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Major Depressive Disorder","enrollment":510},{"nctId":"NCT00252356","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT00252330","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Major Depressive Disorder","enrollment":476},{"nctId":"NCT00252343","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Anxiety Disorder","enrollment":360},{"nctId":"NCT00676039","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2007-11","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Citalopram HCl","genericName":"Citalopram HCl","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Panic disorder, Obsessive-compulsive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}